Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals
• Safety, efficacy, and feasibility of antifungal prophylaxis and therapy of IFDs with novel posaconazole formulations could be demonstrated. • Stable posaconazole serum levels at steady-state could be shown. • Only a small number of adverse drug reactions rated as at least possibly associated with...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Heimann, Sebastian M. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2019transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
9 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Using methylome data to inform exposome-health association studies: An application to the identification of environmental drivers of child body mass index - Cadiou, Solène ELSEVIER, 2020, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:83 ; year:2019 ; pages:130-138 ; extent:9 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.ijid.2019.04.006 |
|---|
| Katalog-ID: |
ELV046957170 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV046957170 | ||
| 003 | DE-627 | ||
| 005 | 20230626014647.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191021s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2019.04.006 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000638.pica |
| 035 | |a (DE-627)ELV046957170 | ||
| 035 | |a (ELSEVIER)S1201-9712(19)30175-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 690 |a 610 |a 600 |q VZ |
| 084 | |a 30.00 |2 bkl | ||
| 084 | |a 44.13 |2 bkl | ||
| 100 | 1 | |a Heimann, Sebastian M. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals |
| 264 | 1 | |c 2019transfer abstract | |
| 300 | |a 9 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • Safety, efficacy, and feasibility of antifungal prophylaxis and therapy of IFDs with novel posaconazole formulations could be demonstrated. • Stable posaconazole serum levels at steady-state could be shown. • Only a small number of adverse drug reactions rated as at least possibly associated with novel posaconazole formulations were documented. • Relatively high mortality rates in patients with posaconazole salvage therapy or due to rare invasive fungal infections could be shown. • This underlines the urgent need of appropriate empiric and targeted antifungal therapy with respect to both, clinical outcome and associated costs. | ||
| 520 | |a • Safety, efficacy, and feasibility of antifungal prophylaxis and therapy of IFDs with novel posaconazole formulations could be demonstrated. • Stable posaconazole serum levels at steady-state could be shown. • Only a small number of adverse drug reactions rated as at least possibly associated with novel posaconazole formulations were documented. • Relatively high mortality rates in patients with posaconazole salvage therapy or due to rare invasive fungal infections could be shown. • This underlines the urgent need of appropriate empiric and targeted antifungal therapy with respect to both, clinical outcome and associated costs. | ||
| 650 | 7 | |a High-risk patient |2 Elsevier | |
| 650 | 7 | |a Clinical effectiveness |2 Elsevier | |
| 650 | 7 | |a Posaconazole serum level |2 Elsevier | |
| 650 | 7 | |a Invasive fungal infection |2 Elsevier | |
| 650 | 7 | |a Neutropenia |2 Elsevier | |
| 700 | 1 | |a Penack, Olaf |4 oth | |
| 700 | 1 | |a Heinz, Werner J. |4 oth | |
| 700 | 1 | |a Rachow, Tobias |4 oth | |
| 700 | 1 | |a Egerer, Gerlinde |4 oth | |
| 700 | 1 | |a Kessel, Johanna |4 oth | |
| 700 | 1 | |a Claßen, Annika Y. |4 oth | |
| 700 | 1 | |a Vehreschild, Jörg Janne |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Cadiou, Solène ELSEVIER |t Using methylome data to inform exposome-health association studies: An application to the identification of environmental drivers of child body mass index |d 2020 |g Amsterdam [u.a.] |w (DE-627)ELV00389553X |
| 773 | 1 | 8 | |g volume:83 |g year:2019 |g pages:130-138 |g extent:9 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ijid.2019.04.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 30.00 |j Naturwissenschaften allgemein: Allgemeines |q VZ |
| 936 | b | k | |a 44.13 |j Medizinische Ökologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 83 |j 2019 |h 130-138 |g 9 | ||
| author_variant |
s m h sm smh |
|---|---|
| matchkey_str |
heimannsebastianmpenackolafheinzwernerjr:2019----:nrvnuadaltomltoopscnzliatfnateaynpohlxsrtopcieoitretoamlietrnlssfea |
| hierarchy_sort_str |
2019transfer abstract |
| bklnumber |
30.00 44.13 |
| publishDate |
2019 |
| allfields |
10.1016/j.ijid.2019.04.006 doi GBV00000000000638.pica (DE-627)ELV046957170 (ELSEVIER)S1201-9712(19)30175-4 DE-627 ger DE-627 rakwb eng 690 610 600 VZ 30.00 bkl 44.13 bkl Heimann, Sebastian M. verfasserin aut Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals 2019transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Safety, efficacy, and feasibility of antifungal prophylaxis and therapy of IFDs with novel posaconazole formulations could be demonstrated. • Stable posaconazole serum levels at steady-state could be shown. • Only a small number of adverse drug reactions rated as at least possibly associated with novel posaconazole formulations were documented. • Relatively high mortality rates in patients with posaconazole salvage therapy or due to rare invasive fungal infections could be shown. • This underlines the urgent need of appropriate empiric and targeted antifungal therapy with respect to both, clinical outcome and associated costs. • Safety, efficacy, and feasibility of antifungal prophylaxis and therapy of IFDs with novel posaconazole formulations could be demonstrated. • Stable posaconazole serum levels at steady-state could be shown. • Only a small number of adverse drug reactions rated as at least possibly associated with novel posaconazole formulations were documented. • Relatively high mortality rates in patients with posaconazole salvage therapy or due to rare invasive fungal infections could be shown. • This underlines the urgent need of appropriate empiric and targeted antifungal therapy with respect to both, clinical outcome and associated costs. High-risk patient Elsevier Clinical effectiveness Elsevier Posaconazole serum level Elsevier Invasive fungal infection Elsevier Neutropenia Elsevier Penack, Olaf oth Heinz, Werner J. oth Rachow, Tobias oth Egerer, Gerlinde oth Kessel, Johanna oth Claßen, Annika Y. oth Vehreschild, Jörg Janne oth Enthalten in Elsevier Cadiou, Solène ELSEVIER Using methylome data to inform exposome-health association studies: An application to the identification of environmental drivers of child body mass index 2020 Amsterdam [u.a.] (DE-627)ELV00389553X volume:83 year:2019 pages:130-138 extent:9 https://doi.org/10.1016/j.ijid.2019.04.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 30.00 Naturwissenschaften allgemein: Allgemeines VZ 44.13 Medizinische Ökologie VZ AR 83 2019 130-138 9 |
| spelling |
10.1016/j.ijid.2019.04.006 doi GBV00000000000638.pica (DE-627)ELV046957170 (ELSEVIER)S1201-9712(19)30175-4 DE-627 ger DE-627 rakwb eng 690 610 600 VZ 30.00 bkl 44.13 bkl Heimann, Sebastian M. verfasserin aut Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals 2019transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Safety, efficacy, and feasibility of antifungal prophylaxis and therapy of IFDs with novel posaconazole formulations could be demonstrated. • Stable posaconazole serum levels at steady-state could be shown. • Only a small number of adverse drug reactions rated as at least possibly associated with novel posaconazole formulations were documented. • Relatively high mortality rates in patients with posaconazole salvage therapy or due to rare invasive fungal infections could be shown. • This underlines the urgent need of appropriate empiric and targeted antifungal therapy with respect to both, clinical outcome and associated costs. • Safety, efficacy, and feasibility of antifungal prophylaxis and therapy of IFDs with novel posaconazole formulations could be demonstrated. • Stable posaconazole serum levels at steady-state could be shown. • Only a small number of adverse drug reactions rated as at least possibly associated with novel posaconazole formulations were documented. • Relatively high mortality rates in patients with posaconazole salvage therapy or due to rare invasive fungal infections could be shown. • This underlines the urgent need of appropriate empiric and targeted antifungal therapy with respect to both, clinical outcome and associated costs. High-risk patient Elsevier Clinical effectiveness Elsevier Posaconazole serum level Elsevier Invasive fungal infection Elsevier Neutropenia Elsevier Penack, Olaf oth Heinz, Werner J. oth Rachow, Tobias oth Egerer, Gerlinde oth Kessel, Johanna oth Claßen, Annika Y. oth Vehreschild, Jörg Janne oth Enthalten in Elsevier Cadiou, Solène ELSEVIER Using methylome data to inform exposome-health association studies: An application to the identification of environmental drivers of child body mass index 2020 Amsterdam [u.a.] (DE-627)ELV00389553X volume:83 year:2019 pages:130-138 extent:9 https://doi.org/10.1016/j.ijid.2019.04.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 30.00 Naturwissenschaften allgemein: Allgemeines VZ 44.13 Medizinische Ökologie VZ AR 83 2019 130-138 9 |
| allfields_unstemmed |
10.1016/j.ijid.2019.04.006 doi GBV00000000000638.pica (DE-627)ELV046957170 (ELSEVIER)S1201-9712(19)30175-4 DE-627 ger DE-627 rakwb eng 690 610 600 VZ 30.00 bkl 44.13 bkl Heimann, Sebastian M. verfasserin aut Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals 2019transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Safety, efficacy, and feasibility of antifungal prophylaxis and therapy of IFDs with novel posaconazole formulations could be demonstrated. • Stable posaconazole serum levels at steady-state could be shown. • Only a small number of adverse drug reactions rated as at least possibly associated with novel posaconazole formulations were documented. • Relatively high mortality rates in patients with posaconazole salvage therapy or due to rare invasive fungal infections could be shown. • This underlines the urgent need of appropriate empiric and targeted antifungal therapy with respect to both, clinical outcome and associated costs. • Safety, efficacy, and feasibility of antifungal prophylaxis and therapy of IFDs with novel posaconazole formulations could be demonstrated. • Stable posaconazole serum levels at steady-state could be shown. • Only a small number of adverse drug reactions rated as at least possibly associated with novel posaconazole formulations were documented. • Relatively high mortality rates in patients with posaconazole salvage therapy or due to rare invasive fungal infections could be shown. • This underlines the urgent need of appropriate empiric and targeted antifungal therapy with respect to both, clinical outcome and associated costs. High-risk patient Elsevier Clinical effectiveness Elsevier Posaconazole serum level Elsevier Invasive fungal infection Elsevier Neutropenia Elsevier Penack, Olaf oth Heinz, Werner J. oth Rachow, Tobias oth Egerer, Gerlinde oth Kessel, Johanna oth Claßen, Annika Y. oth Vehreschild, Jörg Janne oth Enthalten in Elsevier Cadiou, Solène ELSEVIER Using methylome data to inform exposome-health association studies: An application to the identification of environmental drivers of child body mass index 2020 Amsterdam [u.a.] (DE-627)ELV00389553X volume:83 year:2019 pages:130-138 extent:9 https://doi.org/10.1016/j.ijid.2019.04.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 30.00 Naturwissenschaften allgemein: Allgemeines VZ 44.13 Medizinische Ökologie VZ AR 83 2019 130-138 9 |
| allfieldsGer |
10.1016/j.ijid.2019.04.006 doi GBV00000000000638.pica (DE-627)ELV046957170 (ELSEVIER)S1201-9712(19)30175-4 DE-627 ger DE-627 rakwb eng 690 610 600 VZ 30.00 bkl 44.13 bkl Heimann, Sebastian M. verfasserin aut Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals 2019transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Safety, efficacy, and feasibility of antifungal prophylaxis and therapy of IFDs with novel posaconazole formulations could be demonstrated. • Stable posaconazole serum levels at steady-state could be shown. • Only a small number of adverse drug reactions rated as at least possibly associated with novel posaconazole formulations were documented. • Relatively high mortality rates in patients with posaconazole salvage therapy or due to rare invasive fungal infections could be shown. • This underlines the urgent need of appropriate empiric and targeted antifungal therapy with respect to both, clinical outcome and associated costs. • Safety, efficacy, and feasibility of antifungal prophylaxis and therapy of IFDs with novel posaconazole formulations could be demonstrated. • Stable posaconazole serum levels at steady-state could be shown. • Only a small number of adverse drug reactions rated as at least possibly associated with novel posaconazole formulations were documented. • Relatively high mortality rates in patients with posaconazole salvage therapy or due to rare invasive fungal infections could be shown. • This underlines the urgent need of appropriate empiric and targeted antifungal therapy with respect to both, clinical outcome and associated costs. High-risk patient Elsevier Clinical effectiveness Elsevier Posaconazole serum level Elsevier Invasive fungal infection Elsevier Neutropenia Elsevier Penack, Olaf oth Heinz, Werner J. oth Rachow, Tobias oth Egerer, Gerlinde oth Kessel, Johanna oth Claßen, Annika Y. oth Vehreschild, Jörg Janne oth Enthalten in Elsevier Cadiou, Solène ELSEVIER Using methylome data to inform exposome-health association studies: An application to the identification of environmental drivers of child body mass index 2020 Amsterdam [u.a.] (DE-627)ELV00389553X volume:83 year:2019 pages:130-138 extent:9 https://doi.org/10.1016/j.ijid.2019.04.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 30.00 Naturwissenschaften allgemein: Allgemeines VZ 44.13 Medizinische Ökologie VZ AR 83 2019 130-138 9 |
| allfieldsSound |
10.1016/j.ijid.2019.04.006 doi GBV00000000000638.pica (DE-627)ELV046957170 (ELSEVIER)S1201-9712(19)30175-4 DE-627 ger DE-627 rakwb eng 690 610 600 VZ 30.00 bkl 44.13 bkl Heimann, Sebastian M. verfasserin aut Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals 2019transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Safety, efficacy, and feasibility of antifungal prophylaxis and therapy of IFDs with novel posaconazole formulations could be demonstrated. • Stable posaconazole serum levels at steady-state could be shown. • Only a small number of adverse drug reactions rated as at least possibly associated with novel posaconazole formulations were documented. • Relatively high mortality rates in patients with posaconazole salvage therapy or due to rare invasive fungal infections could be shown. • This underlines the urgent need of appropriate empiric and targeted antifungal therapy with respect to both, clinical outcome and associated costs. • Safety, efficacy, and feasibility of antifungal prophylaxis and therapy of IFDs with novel posaconazole formulations could be demonstrated. • Stable posaconazole serum levels at steady-state could be shown. • Only a small number of adverse drug reactions rated as at least possibly associated with novel posaconazole formulations were documented. • Relatively high mortality rates in patients with posaconazole salvage therapy or due to rare invasive fungal infections could be shown. • This underlines the urgent need of appropriate empiric and targeted antifungal therapy with respect to both, clinical outcome and associated costs. High-risk patient Elsevier Clinical effectiveness Elsevier Posaconazole serum level Elsevier Invasive fungal infection Elsevier Neutropenia Elsevier Penack, Olaf oth Heinz, Werner J. oth Rachow, Tobias oth Egerer, Gerlinde oth Kessel, Johanna oth Claßen, Annika Y. oth Vehreschild, Jörg Janne oth Enthalten in Elsevier Cadiou, Solène ELSEVIER Using methylome data to inform exposome-health association studies: An application to the identification of environmental drivers of child body mass index 2020 Amsterdam [u.a.] (DE-627)ELV00389553X volume:83 year:2019 pages:130-138 extent:9 https://doi.org/10.1016/j.ijid.2019.04.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 30.00 Naturwissenschaften allgemein: Allgemeines VZ 44.13 Medizinische Ökologie VZ AR 83 2019 130-138 9 |
| language |
English |
| source |
Enthalten in Using methylome data to inform exposome-health association studies: An application to the identification of environmental drivers of child body mass index Amsterdam [u.a.] volume:83 year:2019 pages:130-138 extent:9 |
| sourceStr |
Enthalten in Using methylome data to inform exposome-health association studies: An application to the identification of environmental drivers of child body mass index Amsterdam [u.a.] volume:83 year:2019 pages:130-138 extent:9 |
| format_phy_str_mv |
Article |
| bklname |
Naturwissenschaften allgemein: Allgemeines Medizinische Ökologie |
| institution |
findex.gbv.de |
| topic_facet |
High-risk patient Clinical effectiveness Posaconazole serum level Invasive fungal infection Neutropenia |
| dewey-raw |
690 |
| isfreeaccess_bool |
false |
| container_title |
Using methylome data to inform exposome-health association studies: An application to the identification of environmental drivers of child body mass index |
| authorswithroles_txt_mv |
Heimann, Sebastian M. @@aut@@ Penack, Olaf @@oth@@ Heinz, Werner J. @@oth@@ Rachow, Tobias @@oth@@ Egerer, Gerlinde @@oth@@ Kessel, Johanna @@oth@@ Claßen, Annika Y. @@oth@@ Vehreschild, Jörg Janne @@oth@@ |
| publishDateDaySort_date |
2019-01-01T00:00:00Z |
| hierarchy_top_id |
ELV00389553X |
| dewey-sort |
3690 |
| id |
ELV046957170 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV046957170</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626014647.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">191021s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ijid.2019.04.006</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000638.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV046957170</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1201-9712(19)30175-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">690</subfield><subfield code="a">610</subfield><subfield code="a">600</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">30.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.13</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Heimann, Sebastian M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Safety, efficacy, and feasibility of antifungal prophylaxis and therapy of IFDs with novel posaconazole formulations could be demonstrated. • Stable posaconazole serum levels at steady-state could be shown. • Only a small number of adverse drug reactions rated as at least possibly associated with novel posaconazole formulations were documented. • Relatively high mortality rates in patients with posaconazole salvage therapy or due to rare invasive fungal infections could be shown. • This underlines the urgent need of appropriate empiric and targeted antifungal therapy with respect to both, clinical outcome and associated costs.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Safety, efficacy, and feasibility of antifungal prophylaxis and therapy of IFDs with novel posaconazole formulations could be demonstrated. • Stable posaconazole serum levels at steady-state could be shown. • Only a small number of adverse drug reactions rated as at least possibly associated with novel posaconazole formulations were documented. • Relatively high mortality rates in patients with posaconazole salvage therapy or due to rare invasive fungal infections could be shown. • This underlines the urgent need of appropriate empiric and targeted antifungal therapy with respect to both, clinical outcome and associated costs.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">High-risk patient</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Clinical effectiveness</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Posaconazole serum level</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Invasive fungal infection</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Neutropenia</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Penack, Olaf</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Heinz, Werner J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rachow, Tobias</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Egerer, Gerlinde</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kessel, Johanna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Claßen, Annika Y.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vehreschild, Jörg Janne</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Cadiou, Solène ELSEVIER</subfield><subfield code="t">Using methylome data to inform exposome-health association studies: An application to the identification of environmental drivers of child body mass index</subfield><subfield code="d">2020</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV00389553X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:83</subfield><subfield code="g">year:2019</subfield><subfield code="g">pages:130-138</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ijid.2019.04.006</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">30.00</subfield><subfield code="j">Naturwissenschaften allgemein: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.13</subfield><subfield code="j">Medizinische Ökologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">83</subfield><subfield code="j">2019</subfield><subfield code="h">130-138</subfield><subfield code="g">9</subfield></datafield></record></collection>
|
| author |
Heimann, Sebastian M. |
| spellingShingle |
Heimann, Sebastian M. ddc 690 bkl 30.00 bkl 44.13 Elsevier High-risk patient Elsevier Clinical effectiveness Elsevier Posaconazole serum level Elsevier Invasive fungal infection Elsevier Neutropenia Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals |
| authorStr |
Heimann, Sebastian M. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV00389553X |
| format |
electronic Article |
| dewey-ones |
690 - Buildings 610 - Medicine & health 600 - Technology |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
690 610 600 VZ 30.00 bkl 44.13 bkl Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals High-risk patient Elsevier Clinical effectiveness Elsevier Posaconazole serum level Elsevier Invasive fungal infection Elsevier Neutropenia Elsevier |
| topic |
ddc 690 bkl 30.00 bkl 44.13 Elsevier High-risk patient Elsevier Clinical effectiveness Elsevier Posaconazole serum level Elsevier Invasive fungal infection Elsevier Neutropenia |
| topic_unstemmed |
ddc 690 bkl 30.00 bkl 44.13 Elsevier High-risk patient Elsevier Clinical effectiveness Elsevier Posaconazole serum level Elsevier Invasive fungal infection Elsevier Neutropenia |
| topic_browse |
ddc 690 bkl 30.00 bkl 44.13 Elsevier High-risk patient Elsevier Clinical effectiveness Elsevier Posaconazole serum level Elsevier Invasive fungal infection Elsevier Neutropenia |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
o p op w j h wj wjh t r tr g e ge j k jk a y c ay ayc j j v jj jjv |
| hierarchy_parent_title |
Using methylome data to inform exposome-health association studies: An application to the identification of environmental drivers of child body mass index |
| hierarchy_parent_id |
ELV00389553X |
| dewey-tens |
690 - Building & construction 610 - Medicine & health 600 - Technology |
| hierarchy_top_title |
Using methylome data to inform exposome-health association studies: An application to the identification of environmental drivers of child body mass index |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV00389553X |
| title |
Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals |
| ctrlnum |
(DE-627)ELV046957170 (ELSEVIER)S1201-9712(19)30175-4 |
| title_full |
Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals |
| author_sort |
Heimann, Sebastian M. |
| journal |
Using methylome data to inform exposome-health association studies: An application to the identification of environmental drivers of child body mass index |
| journalStr |
Using methylome data to inform exposome-health association studies: An application to the identification of environmental drivers of child body mass index |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2019 |
| contenttype_str_mv |
zzz |
| container_start_page |
130 |
| author_browse |
Heimann, Sebastian M. |
| container_volume |
83 |
| physical |
9 |
| class |
690 610 600 VZ 30.00 bkl 44.13 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Heimann, Sebastian M. |
| doi_str_mv |
10.1016/j.ijid.2019.04.006 |
| dewey-full |
690 610 600 |
| title_sort |
intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: a retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals |
| title_auth |
Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals |
| abstract |
• Safety, efficacy, and feasibility of antifungal prophylaxis and therapy of IFDs with novel posaconazole formulations could be demonstrated. • Stable posaconazole serum levels at steady-state could be shown. • Only a small number of adverse drug reactions rated as at least possibly associated with novel posaconazole formulations were documented. • Relatively high mortality rates in patients with posaconazole salvage therapy or due to rare invasive fungal infections could be shown. • This underlines the urgent need of appropriate empiric and targeted antifungal therapy with respect to both, clinical outcome and associated costs. |
| abstractGer |
• Safety, efficacy, and feasibility of antifungal prophylaxis and therapy of IFDs with novel posaconazole formulations could be demonstrated. • Stable posaconazole serum levels at steady-state could be shown. • Only a small number of adverse drug reactions rated as at least possibly associated with novel posaconazole formulations were documented. • Relatively high mortality rates in patients with posaconazole salvage therapy or due to rare invasive fungal infections could be shown. • This underlines the urgent need of appropriate empiric and targeted antifungal therapy with respect to both, clinical outcome and associated costs. |
| abstract_unstemmed |
• Safety, efficacy, and feasibility of antifungal prophylaxis and therapy of IFDs with novel posaconazole formulations could be demonstrated. • Stable posaconazole serum levels at steady-state could be shown. • Only a small number of adverse drug reactions rated as at least possibly associated with novel posaconazole formulations were documented. • Relatively high mortality rates in patients with posaconazole salvage therapy or due to rare invasive fungal infections could be shown. • This underlines the urgent need of appropriate empiric and targeted antifungal therapy with respect to both, clinical outcome and associated costs. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals |
| url |
https://doi.org/10.1016/j.ijid.2019.04.006 |
| remote_bool |
true |
| author2 |
Penack, Olaf Heinz, Werner J. Rachow, Tobias Egerer, Gerlinde Kessel, Johanna Claßen, Annika Y. Vehreschild, Jörg Janne |
| author2Str |
Penack, Olaf Heinz, Werner J. Rachow, Tobias Egerer, Gerlinde Kessel, Johanna Claßen, Annika Y. Vehreschild, Jörg Janne |
| ppnlink |
ELV00389553X |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.ijid.2019.04.006 |
| up_date |
2024-07-06T21:34:58.587Z |
| _version_ |
1803867073899659264 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV046957170</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626014647.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">191021s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ijid.2019.04.006</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000638.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV046957170</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1201-9712(19)30175-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">690</subfield><subfield code="a">610</subfield><subfield code="a">600</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">30.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.13</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Heimann, Sebastian M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Safety, efficacy, and feasibility of antifungal prophylaxis and therapy of IFDs with novel posaconazole formulations could be demonstrated. • Stable posaconazole serum levels at steady-state could be shown. • Only a small number of adverse drug reactions rated as at least possibly associated with novel posaconazole formulations were documented. • Relatively high mortality rates in patients with posaconazole salvage therapy or due to rare invasive fungal infections could be shown. • This underlines the urgent need of appropriate empiric and targeted antifungal therapy with respect to both, clinical outcome and associated costs.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Safety, efficacy, and feasibility of antifungal prophylaxis and therapy of IFDs with novel posaconazole formulations could be demonstrated. • Stable posaconazole serum levels at steady-state could be shown. • Only a small number of adverse drug reactions rated as at least possibly associated with novel posaconazole formulations were documented. • Relatively high mortality rates in patients with posaconazole salvage therapy or due to rare invasive fungal infections could be shown. • This underlines the urgent need of appropriate empiric and targeted antifungal therapy with respect to both, clinical outcome and associated costs.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">High-risk patient</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Clinical effectiveness</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Posaconazole serum level</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Invasive fungal infection</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Neutropenia</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Penack, Olaf</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Heinz, Werner J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rachow, Tobias</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Egerer, Gerlinde</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kessel, Johanna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Claßen, Annika Y.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vehreschild, Jörg Janne</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Cadiou, Solène ELSEVIER</subfield><subfield code="t">Using methylome data to inform exposome-health association studies: An application to the identification of environmental drivers of child body mass index</subfield><subfield code="d">2020</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV00389553X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:83</subfield><subfield code="g">year:2019</subfield><subfield code="g">pages:130-138</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ijid.2019.04.006</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">30.00</subfield><subfield code="j">Naturwissenschaften allgemein: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.13</subfield><subfield code="j">Medizinische Ökologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">83</subfield><subfield code="j">2019</subfield><subfield code="h">130-138</subfield><subfield code="g">9</subfield></datafield></record></collection>
|
| score |
7.398492 |